Literature DB >> 15648014

The myopathy of statins.

Miroslaw Smogorzewski1.   

Abstract

Statins are first-line drugs for prevention and treatment of hypercholesterolemia and atherosclerotic disease. Despite the fact that statins are generally well tolerated and have a positive impact on human health, their myotoxic properties should keep physicians on alert. Mechanisms of statin-induced myopathy are still not fully understood. Phenotypic characteristics of patients, individual statin properties, and metabolic interaction with other drugs are important factors that may increase risk for statin myopathy. The lowest effective dose of statin should be used during treatment. Early recognition of myopathy and discontinuation of statin is critical in preventing serious sequelae such as rhabdomyolysis with all its complications.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15648014     DOI: 10.1053/j.jrn.2004.09.033

Source DB:  PubMed          Journal:  J Ren Nutr        ISSN: 1051-2276            Impact factor:   3.655


  4 in total

Review 1.  How do you treat patients with myalgia who take statins?

Authors:  Saadi A Siddiqi; Paul D Thompson
Journal:  Curr Atheroscler Rep       Date:  2009-01       Impact factor: 5.113

Review 2.  Statins and New-Onset Diabetes in Cardiovascular and Kidney Disease Cohorts: A Meta-Analysis.

Authors:  Haroon Kamran; Eric Kupferstein; Navneet Sharma; Jocelyne G Karam; Alyson K Myers; Irini Youssef; James R Sowers; Deborah R Gustafson; Moro O Salifu; Samy I McFarlane
Journal:  Cardiorenal Med       Date:  2018-01-22       Impact factor: 2.041

3.  Extended release niacin-laropiprant in patients with hypercholesterolemia or mixed dyslipidemias improves clinical parameters.

Authors:  Helen Vosper
Journal:  Clin Med Insights Cardiol       Date:  2011-09-19

4.  Evaluation of sexual dimorphism in the efficacy and safety of simvastatin/atorvastatin therapy in a southern Brazilian cohort.

Authors:  Lisiane Smiderle; Luciana O Lima; Mara Helena Hutz; Cézar Roberto Van der Sand; Luiz Carlos Van der Sand; Maria Elvira Wagner Ferreira; Renan Canibal Pires; Silvana Almeida; Marilu Fiegenbaum
Journal:  Arq Bras Cardiol       Date:  2014-07       Impact factor: 2.000

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.